Company Name, Ticker, Customers, else..

Epizyme Inc. (NASDAQ: EPZM)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Epizyme Inc's

Name: Epizyme Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

EPZM Sales vs. its Competitors Q2 2022

Comparing the current results to its competitors, Epizyme Inc reported Revenue increase in the 2 quarter 2022 by 111.59 % year on year.
The sales growth was above Epizyme Inc's competitors' average revenue growth of 83.54 %, achieved in the same quarter.

• List of EPZM Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Epizyme Inc. recorded a net loss, as well as most of its competitors.

<< EPZM Stock Performance Comparisons

<< See the full list of EPZM competitors

Overall company Market Share Q2 2022

Due to outstanding performance in Overall company, revenue grew by 111.59 % Epizyme Inc has increased its market share in this segment. << More on EPZM Market Share.

*Market share is calculated based on total revenue.

EPZM's Stock Performance relative to its Competitors

Publicly Traded Peers of Epizyme Inc.

Atossa Therapeutics Inc
Share Performance

+4.13%

30 Days

Atossa Therapeutics Inc

Profile

Atossa Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for breast conditions and oncology.

More about Atossa Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 22.449 mill.	$ - mill.	$ -37.709 mill.

Bio Green Med Solution Inc
Share Performance

-87.31%

One Year

Bio Green Med Solution Inc

Profile

Bio Green Med Solution supplies and trades fire safety equipment and protective products.

More about Bio Green Med Solution Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 5.058 mill.	$ 1.861 mill.	$ -13.234 mill.

G1 Therapeutics Inc
Share Performance

+129.90%

This Year

G1 Therapeutics Inc

Profile

G1 Therapeutics Inc is a biopharmaceutical company that operates under a research and development business model. They focus on discovering, developing, and commercializing novel therapies to address unmet needs in cancer treatment, with a strong emphasis on targeting specific cellular processes. Their business model involves conducting preclinical and clinical trials, obtaining regulatory approvals, and collaborating with strategic partners to bring their innovative drugs to market.

More about G1 Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 375.198 mill.	$ 58.195 mill.	$ -44.770 mill.

Kronos Bio Inc
Share Performance

+27.91%

30 Days

Kronos Bio Inc

Profile

Kronos Bio Inc's business model focuses on developing therapeutics for the treatment of cancer. They utilize a precision medicine approach to target and inhibit novel transcription factors, which play a critical role in the progression of various types of cancer.

More about Kronos Bio Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 53.510 mill.	$ 9.192 mill.	$ -64.485 mill.

Maia Biotechnology Inc
Share Performance

-7.04%

30 Days

Maia Biotechnology Inc

Profile

Maia Biotechnology Inc is a biotechnology company that focuses on developing innovative therapies for cancer treatment. Their business model revolves around leveraging advanced genomic technologies to identify novel targets for drug development. By combining their expertise in genomics and drug discovery, they aim to create personalized and targeted therapies to improve patient outcomes in the field of oncology.

More about Maia Biotechnology Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 80.249 mill.	$ - mill.	$ -26.845 mill.

3 more competitors available

Sources: Epizyme Inc.’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Sunday, August 30, 2026 7:08 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Epizyme Inc. versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.